HDAC9 and Miyoshi myopathy: We previously showed that MAGE-A expression was associated with short progression free survival in a clinical trial of panobinostat (a pan-HDAC inhibitor)-based chemotherapy, and that loss of MAGE-A sensitized HMCL to panobinostat but not lenalidomide, an immunomodulatory drug commonly used in MM [10].